尽管公司缺乏收入预期,但遗产财务顾问购买了更多的Vertex制药公司股票。 Legacy Financial Advisors bought more Vertex Pharmaceuticals stock despite the company missing earnings expectations.

遗留财务顾问在Vertex制药公司(VRTX)的股票持有量增加了4.2%,获得了另外104个股份,拥有2 552个股份。 Legacy Financial Advisors increased its stock holdings in Vertex Pharmaceuticals (VRTX) by 4.2%, acquiring an additional 104 shares to own 2,552 shares. Vertex制药公司是一家生物技术公司,重点处理细胞纤维化治疗,最近错过了每股收入0.45美元的预期。 Vertex Pharmaceuticals, a biotech firm focused on cystic fibrosis treatments, recently missed earnings expectations by $0.45 per share. 分析员预测,Vertex公司将在本年度将按每股15.63美元的收入计算,协商一致目标价格为509.17美元。 Analysts predict Vertex will post 15.63 earnings per share for the year, with a consensus target price of $509.17.